Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug withdrawal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,361 result(s) found for: Drug withdrawal. Displaying page 1 of 69.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-001043-37 Sponsor Protocol Number: LORA01 Start Date*: 2015-06-30
    Sponsor Name:Erasmus MC
    Full Title: Pharmacokinetics of Lorazepam Oral Liquid in Paediatric ICU Patients
    Medical condition: Withdrawal
    Disease: Version SOC Term Classification Code Term Level
    19.0 10018065 - General disorders and administration site conditions 10013754 Drug withdrawal syndrome PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002072-26 Sponsor Protocol Number: P150939 Start Date*: 2016-08-25
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Multicenter randomized placebo controlled trial assessing the efficacy of oral adjuvant magnesium supplementation in the treatment of alcohol withdrawal syndrome.
    Medical condition: Patients experiencing an alcohol withdrawal syndrome.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10037175 - Psychiatric disorders 10053164 Alcohol withdrawal syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005319-28 Sponsor Protocol Number: CNWL/AL/BACL/01 Start Date*: 2015-03-13
    Sponsor Name:Central and North West London NHS Foundation Trust
    Full Title: Improving GHB withdrawal with baclofen (The GHB Trial)
    Medical condition: GHB/GBL Withdrawal Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001486-33 Sponsor Protocol Number: Kep-F10.3.01 Start Date*: 2006-04-27
    Sponsor Name:Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie
    Full Title: Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome [Sicherheit und Wirksamkeit von Levetiracetam (Keppra) für die Behandlung des stationären Alkoholentzu...
    Medical condition: alcohol withdrawal syndrome (AWS) in inpatients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004557-14 Sponsor Protocol Number: NA Start Date*: 2015-02-09
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King’s College Hospital NHS Foundation Trust
    Full Title: Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation
    Medical condition: Immunosuppression withdrawal in liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005971-18 Sponsor Protocol Number: 13-617 Start Date*: 2014-01-24
    Sponsor Name:University Medical Center Utrecht
    Full Title: TimeToStop (TTS) Trial, A randomised controlled trial of early versus late antiepileptic drug withdrawal after pediatric epilepsy surgery
    Medical condition: We will investigate possible cognitive benifits of early antiepileptic drug withdrawal after pediatric epilepsy surgery. The concerning medical condition is refractory epilepsy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000251-39 Sponsor Protocol Number: TAK-994-1504 Start Date*: 2021-08-12
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults Wi...
    Medical condition: Narcolepsy With Cataplexy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005235-14 Sponsor Protocol Number: P05042 Start Date*: 2007-07-11
    Sponsor Name:Integrated Therapeutics Group Inc
    Full Title: A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users
    Medical condition: Opioid dependence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013663 Drug dependence LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) ES (Completed) CZ (Completed) PT (Completed) SI (Completed) DE (Completed) IE (Completed) IT (Completed) LT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003254-91 Sponsor Protocol Number: AGO/2019/005 Start Date*: 2020-08-18
    Sponsor Name:Ghent University Hospital
    Full Title: Characterisation and intervention study in patients with long-term use of nasal decongestants.
    Medical condition: rhinitis medicamentosa
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-000426-20 Sponsor Protocol Number: 15-006 Start Date*: 2016-09-05
    Sponsor Name:Jazz Pharmaceuticals
    Full Title: A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy
    Medical condition: Treatment of cataplexy in narcolepsy Treatment of excessive daytime sleepiness (EDS) in narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10015595 Excessive daytime sleepiness LLT
    20.0 100000004852 10007738 Cataplexy and narcolepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) FI (Completed) HR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002708-26 Sponsor Protocol Number: CRC341 Start Date*: 2017-06-28
    Sponsor Name:University of Surrey
    Full Title: A randomised double blind placebo controlled pilot trial of oxytocin efficacy in treating detoxified opioid dependent individuals
    Medical condition: Opioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individua...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10057379 Addiction relapse LLT
    20.0 100000004873 10001126 Addiction any drug LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000630-22 Sponsor Protocol Number: TV50717-CNS-30047 Start Date*: 2018-06-05
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children a...
    Medical condition: Tics associated with Tourette Syndrome(TS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Completed) FR (Completed) NL (Ongoing) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004775-36 Sponsor Protocol Number: DETOX-11 Start Date*: 2012-01-30
    Sponsor Name:GET SRL
    Full Title: ''A Phase III, multicenter, open-label study, to evaluate the efficacy and safety of different dosage regimens of 0.2 mg lofexidine hydrochloride (DIMATEX) in the treatment of withdrawal symptoms d...
    Medical condition: Oppiate addicts(heroin, methadone and buprenorphine)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10032707 Other specified drug dependence, continuous use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000570-35 Sponsor Protocol Number: 01-2015 Start Date*: 2016-02-10
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Prophylaxis of Hepatitis B reactivation in patients with HBV occult infection and rheumatological diseases candidates to immune suppressive treatments of finite duration.
    Medical condition: Occult Hepatitis B virus Infection (OBI) in patients with rheumatologic diseases candidate to treatment a finite duration (less than 18 months) with potent immune suppressive drugs
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037163 Psoriatic arthropathies HLT
    20.1 100000004862 10057212 Hepatitis viral infections HLT
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002899-41 Sponsor Protocol Number: 8-55-52966-005 Start Date*: 2014-04-28
    Sponsor Name:Ipsen Pharma
    Full Title: A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and the pharmacodynamic of BN82451B, administered twice daily over 4 weeks, in ...
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023342-67 Sponsor Protocol Number: C38072/3081 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) wit...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002500-91 Sponsor Protocol Number: RPC01-3001 Start Date*: 2015-10-12
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015647-16 Sponsor Protocol Number: ANV-09-008 Start Date*: 2010-01-28
    Sponsor Name:GUIDE Clinic, St James's Hospital
    Full Title: The pharmacokinetics of once daily Kaletra and methadone in a population of HIV positiive drug users.
    Medical condition: HIV-1 Positive Injection Drug Users
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020180 HIV positive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020005-32 Sponsor Protocol Number: A3921111 Start Date*: 2011-02-08
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVE...
    Medical condition: Chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004122-17 Sponsor Protocol Number: iSPOT-D Start Date*: 2008-08-29
    Sponsor Name:BRC operations Pty. Ltd.
    Full Title: International Study to Predict Optimised Treatment - in Depression iSPOT-D
    Medical condition: Patients suffering from major depressive disorder (MDD) as well as healthy control participants. Only patients will receive medication which will be 'treatment as usual'.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 22:23:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA